Awaiting development: Guidance and quality standards

Showing 171 to 180 of 335

Guidance and quality standards awaiting development
Title	Type
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TS ID 12048]	Technology appraisal guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593	Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis TS ID 11958	Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044	Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523	Technology appraisal guidance
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]	Technology appraisal guidance
Nirogacestat for treating desmoid tumours TSID 12039	Technology appraisal guidance
Nitazoxanide for treating the common cold in people 12 years and over TS ID 10548	Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance